Business Context and Reporting Period
Company: Coherus Oncology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 5, 2025
Reporting Period: Event-based report regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock price.
Material Changes
- Regulatory Status Change: The Company resolved a deficiency notice previously issued by Nasdaq on June 30, 2025, regarding the closing bid price of its common stock falling below $1.00 per share for 30 consecutive business days.
- Compliance Regained: As of September 5, 2025, Nasdaq confirmed the Company's stock closed at $1.00 or greater for the requisite period, satisfying Listing Rule 5550(a)(2).
- Outcome: The matter is closed, and the Company is in full compliance with all continued listing standards of the Nasdaq Global Market.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the resolution of the listing deficiency without providing additional strategic guidance or financial outlook.
Risks and Contingencies: The risk of delisting due to low stock price has been mitigated as of the report date. No new risks or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of CHRS on the Nasdaq Global Market to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the Company's most recent 10-Q or 10-K for financial performance metrics, as this 8-K contains no financial data.
- Monitor future Nasdaq communications to ensure no new deficiency notices are issued regarding stock price or other listing standards.